UBS Raises Price Target on Pharmerica (PMC) to $27; Remains Neutral
Tweet Send to a Friend
UBS reiterated a Neutral rating on PharMerica (NYSE: PMC), and raised the price target to $27.00 (from $22.00), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
